Physician profile
Daniel S Berger
NPI 1710076237
$24,083.61
in general payments reported to CMS, 2019-2025
22 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $5,622 · 2021: $1,339 · 2022: $12.17 · 2023: $72.25 · 2024: $149 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536 · Education: $10.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.63 |
| Education | $10.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $22,158.75 | 2019-2025 | |
| Janssen Products, LP | $500.00 | 2020 | |
| Janssen Biotech, INC. | $269.67 | 2019-2020 | |
| Amgen INC. | $223.81 | 2019-2025 | Repatha, Otezla |
| Pfizer INC. | $132.34 | 2019-2020 | |
| Abbvie INC. | $99.27 | 2021-2024 | |
| Viiv Healthcare Company | $91.15 | 2024-2025 | Cabenuva, Dovato, Apretude |
| Merck Sharp & Dohme LLC | $88.60 | 2019-2023 | Delstrigo, Pifeltro |
| Novo Nordisk INC | $79.05 | 2019-2024 | Rybelsus, Ozempic |
| Antares Pharma, INC. | $78.76 | 2019 | |
| Allergan, INC. | $51.60 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $45.74 | 2025 | Iqirvo |
| Novartis Pharmaceuticals Corporation | $43.38 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.26 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $34.27 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $32.99 | 2019-2020 | |
| Inspire Medical Systems, INC. | $25.00 | 2024 | Inspire |
| Genentech USA, INC. | $20.75 | 2019 | |
| Axsome Therapeutics, INC. | $19.66 | 2023 | Auvelity |
| Nestle Healthcare Nutrition INC. | $17.28 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.62 | 2023 | Symtuza |
| Upsher-Smith Laboratories LLC | $13.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.